France Bioproduction Congress’ Post

Let’s connect

Thank you Ester Caffarel-Salvador, PhD, Director of Strategic Innovation for Rare Diseases at Chiesi Global Rare Diseases for joining us at BIO2024 for an interview on "Innovation in the Pharma World" Here's a glimpse of what you'll discover in this episode of our b.empowered podcast series: 🌐 Chiesi, a family-owned global pharmaceutical R&D company from Italy, is dedicated to tackling rare diseases through three main business units: air (respiratory diseases), care (neonatology and transplant products), and rare (rare diseases). 🔬 Chiesi's Strategic Innovation unit is breaking new ground by exploring therapeutic modalities beyond small molecules and biologics to find life-changing cures for rare diseases. 🤝 Chiesi’s collaboration with patient advocacy groups and their support for cutting-edge research and technology underscores their commitment to fostering innovation in rare diseases. 🇺🇸 The partnership between Chiesi and BioLabs extends Chiesi's reach in the US, connecting them with startups, investors, and key stakeholders in the rare disease community. 🏆 Through the successful Golden Ticket program, Chiesi and BioLabs award two companies free lab space and resources at any BioLabs location in the US Ester's insights highlight the power of collaboration and the relentless pursuit of innovation to create a brighter future for those affected by rare diseases. Tune in to be inspired by how Chiesi is making a global impact through strategic partnerships and innovative approaches. 🎧 https://lnkd.in/eb-KsWbf Thanks to John Freeman CPA, MST, CGMA for interviewing Ester. #BIO2024 #Chiesi #BioLabs #EmpoweringInnovationWorldwide #Biotech #Pharma #RareDiseases #bempowered #Podcast #GoldenTicket #Inspiration #Collaboration

[#NEWS] 📣 EMIH is proud to announce a collaboration Agreement with the Microbiome Therapeutics Innovation Group (MTIG) to advance microbiome drug development, explore synergies between international regulators, and convene cross-continental meetings to incorporate the perspectives of a wide-range of drug developers. 🤝   Herve Affagard, MBA, Eng., President of European Microbiome Innovation for Health stated "𝐴𝑠 𝑙𝑒𝑎𝑑𝑖𝑛𝑔 𝑎𝑠𝑠𝑜𝑐𝑖𝑎𝑡𝑖𝑜𝑛𝑠 𝑖𝑛 𝑡ℎ𝑒 𝑚𝑖𝑐𝑟𝑜𝑏𝑖𝑜𝑚𝑒 𝑓𝑖𝑒𝑙𝑑, 𝑤𝑒 𝑢𝑛𝑑𝑒𝑟𝑠𝑡𝑎𝑛𝑑 𝑡ℎ𝑎𝑡 𝑜𝑢𝑟 𝑠𝑡𝑟𝑒𝑛𝑔𝑡ℎ 𝑙𝑖𝑒𝑠 𝑖𝑛 𝑐𝑜𝑙𝑙𝑎𝑏𝑜𝑟𝑎𝑡𝑖𝑜𝑛. 𝐵𝑦 𝑗𝑜𝑖𝑛𝑖𝑛𝑔 𝑓𝑜𝑟𝑐𝑒𝑠 𝑤𝑖𝑡ℎ 𝑀𝑇𝐼𝐺, 𝑤𝑒 𝑤𝑖𝑙𝑙 𝑎𝑐𝑐𝑒𝑙𝑒𝑟𝑎𝑡𝑒 𝑡ℎ𝑒 𝑑𝑒𝑣𝑒𝑙𝑜𝑝𝑚𝑒𝑛𝑡 𝑎𝑛𝑑 𝑑𝑒𝑙𝑖𝑣𝑒𝑟𝑦 𝑜𝑓 𝑚𝑖𝑐𝑟𝑜𝑏𝑖𝑜𝑚𝑒 𝑡ℎ𝑒𝑟𝑎𝑝𝑖𝑒𝑠, 𝑒𝑛𝑠𝑢𝑟𝑖𝑛𝑔 𝑡ℎ𝑎𝑡 𝑔𝑟𝑜𝑢𝑛𝑑𝑏𝑟𝑒𝑎𝑘𝑖𝑛𝑔 𝑡𝑟𝑒𝑎𝑡𝑚𝑒𝑛𝑡𝑠 𝑟𝑒𝑎𝑐ℎ 𝑡ℎ𝑜𝑠𝑒 𝑤ℎ𝑜 𝑛𝑒𝑒𝑑 𝑡ℎ𝑒𝑚 𝑚𝑜𝑠𝑡, 𝑠𝑤𝑖𝑓𝑡𝑙𝑦 𝑎𝑛𝑑 𝑠𝑎𝑓𝑒𝑙𝑦. “   Nikole Kimes, Chairman of @Microbiome Therapeutics Innovation Group also said: “𝑇ℎ𝑒 𝐸𝑀𝐼𝐻 𝑟𝑒𝑝𝑟𝑒𝑠𝑒𝑛𝑡𝑠 𝑖𝑛𝑛𝑜𝑣𝑎𝑡𝑖𝑣𝑒 𝑚𝑖𝑐𝑟𝑜𝑏𝑖𝑜𝑚𝑒 𝑐𝑜𝑚𝑝𝑎𝑛𝑖𝑒𝑠 𝑎𝑙𝑖𝑔𝑛𝑒𝑑 𝑤𝑖𝑡ℎ 𝑡ℎ𝑖𝑠 𝑐𝑜𝑟𝑒 𝑚𝑖𝑠𝑠𝑖𝑜𝑛, 𝑎𝑛𝑑 𝑤𝑒 𝑙𝑜𝑜𝑘 𝑓𝑜𝑟𝑤𝑎𝑟𝑑 𝑡𝑜 𝑠ℎ𝑎𝑟𝑖𝑛𝑔 𝑖𝑛𝑠𝑖𝑔ℎ𝑡𝑠 𝑤𝑖𝑡ℎ 𝑜𝑛𝑒 𝑎𝑛𝑜𝑡ℎ𝑒𝑟 𝑡𝑜 𝑎𝑚𝑝𝑙𝑖𝑓𝑦 𝑜𝑢𝑟 𝑐𝑜𝑙𝑙𝑒𝑐𝑡𝑖𝑣𝑒 𝑣𝑜𝑖𝑐𝑒 𝑎𝑛𝑑 𝑡𝑟𝑎𝑛𝑠𝑓𝑜𝑟𝑚 𝑡ℎ𝑒 𝑙𝑖𝑣𝑒𝑠 𝑜𝑓 𝑝𝑎𝑡𝑖𝑒𝑛𝑡𝑠 𝑜𝑛 𝑏𝑜𝑡ℎ 𝑠𝑖𝑑𝑒𝑠 𝑜𝑓 𝑡ℎ𝑒 𝐴𝑡𝑙𝑎𝑛𝑡𝑖𝑐.”   💻More information about the collaboration: https://lnkd.in/gqsqUiyY #Microbiome #drudevelopment #collaboration #EMIH #MTIG

Incentives for early stage research into antimicrobial resistance (#AMR), are already a focus in Australia. However, uncertain economic returns mean that pharmaceutical companies and private investors have shied away from funding later-stage research and development. Collaborations between investors and between the private and public sectors are helping to improve the current funding model. Read our article featuring insights from Main Sequence's Dr Elaine Stead. https://lnkd.in/gFMTaNvK #minimisingAMR #antimicrobialresistance #antibioticresistance #funding #publichealth FAIRR Initiative

### History of Roche: Pioneering Healthcare for Over a Century 🌍 Since its inception in 1896, Roche has been at the forefront of pharmaceutical innovation, dedicated to transforming global healthcare. Founded in Basel, Switzerland, by Fritz Hoffmann-La Roche, the company emerged in response to the urgent need for industrial-scale medicine production following the devastating cholera outbreak in Hamburg. Roche quickly expanded internationally, establishing subsidiaries across Europe, Asia, and the Americas by 1912. Despite early challenges, including financial crises during World War I and the Russian Civil War, Roche persevered under the leadership of Emil C. Barell and continued to innovate. In the 1920s, Roche introduced pioneering therapies like the first orange-flavored cough syrup, which became an instant success. This early achievement paved the way for future medical breakthroughs, including the synthesis of vitamin C by Tadeusz Reichstein in the 1930s, marking Roche's entry into the vitamins market and its commitment to improving public health. The company's commitment to oncology became evident in the 1950s, with advancements in cancer treatment that set new standards in the field. Innovations continued through the decades, from the development of diagnostic tools in the 1960s to groundbreaking research in immunology and genetics in the 1980s and beyond. Roche's acquisition of Genentech in 2009 marked a significant milestone, creating the world's largest biotechnology company and enhancing its capabilities in personalized healthcare. This strategic move enabled Roche to integrate genomic insights into its drug development processes, paving the way for precision medicine. Today, Roche remains at the forefront of healthcare innovation, responding swiftly to global health challenges such as the COVID-19 pandemic. By acquiring companies like Flatiron Health and Spark Therapeutics, Roche continues to expand its expertise in data-driven healthcare solutions and genetic therapies, reaffirming its commitment to improving patients' lives worldwide. Through over a century of pioneering spirit and scientific excellence, Roche continues to shape the future of healthcare, striving to make personalized healthcare a reality for all. 🚀💊 #Roche #HealthcareInnovation #PioneeringSpirit #GlobalHealth

This partnership will be key for the biotech and mid size pharma to benefit from both companies competencies to ensure time to market pre-clinial, clinical and commercial product delivery. Looking forward to contributing actively to the France2030 ambition

🌟 Revolutionizing Medicine with DoseMe! 🌟 I had an enlightening conversation with Paul Edwards, the President & CEO of DoseMe, on the latest episode of the Life Science Success Podcast! 🎙️ Here are some key takeaways: Precision in Dosing: DoseMeRx is pioneering precise dosing for critically ill patients, enhancing the efficacy and safety of injectable antibiotics with innovative therapeutic drug monitoring. 💉🔬 Industry Insight: Paul's extensive experience, from leading roles at Merck and GSK to transformative startups, underscores the critical role of real-world data in advancing personalized medicine. 🌍📊 Antimicrobial Stewardship: Emphasizing the importance of antimicrobial stewardship, Paul discusses how DoseMeRx’s technology supports clinicians in delivering the right dose at the right time, improving patient outcomes. 🏥👨⚕️ Future of Medicine: We explored the potential of pharmacogenomics and personalized medicine in shaping the future of healthcare, aiming for treatments tailored to individual patient needs. 🧬🚀 Overcoming Challenges: Addressing current insurance and payment system limitations, Paul highlights the need for systems that better support precision and personalized medicine. 🏛️⚖️ A huge thanks to Paul for sharing his insights and to D3 Digital Media Marketing for sponsoring this episode. Let’s continue to innovate and drive success in life sciences! 👉 Listen to the full episode and join the conversation on advancing healthcare: https://lnkd.in/gn63phKa #LifeScienceSuccess #DoseMeRx #PrecisionMedicine #Pharmacogenomics #DigitalMarketing #HealthcareInnovation #AntimicrobialStewardship

NEWS: University of Louisiana's New Iberia Research Center Breaks Ground on BSL-3 Lab -- The University of Louisiana at Lafayette began construction in June of 2024 on a significant expansion of the New Iberia Research Center, the nation's largest facility for nonhuman primates. Creating an onsite BSL-3 laboratory for the study of infectious diseases and select agents, the $25 million project will enable the development of novel vaccines, diagnostics, and mitigation solutions. Paul J. Allain designed the addition to meet and exceed the standards of the NIH Design Requirements Manual, as well as abiding by the extensive guidelines of the Centers for Disease Control and Prevention and the U.S. Department of Agriculture. The $22 million Iberia BioInnovation Accelerator is also being created to support pharmaceutical manufacturing operations. Together, the two buildings will anchor the Bieaux Tech Technology Hub when they reach completion in mid-2026. https://lnkd.in/e5889cMf #AnimalResearch #Biocontainment #HigherEducation #Biomedical #ResearchAndDevelopment #EmergencyResponse #StrategicPlans

TLDR Biotech for June 25 - 26 𝐀𝐩𝐩𝐫𝐨𝐯𝐚𝐥𝐬: Novo Nordisk's Wegovy approved by Chinese NMPA 💊 + 4 more stories 𝐁𝐮𝐬𝐢𝐧𝐞𝐬𝐬 𝐃𝐞𝐯𝐞𝐥𝐨𝐩𝐦𝐞𝐧𝐭: Just - Evotec Biologics lands $39M DOD project 🌎 𝐂𝐥𝐢𝐧𝐢𝐜𝐚𝐥 𝐓𝐫𝐢𝐚𝐥𝐬: Savara reports positive lung disease Ph3 data 🔬 + 2 more stories 𝐅𝐮𝐧𝐝𝐫𝐚𝐢𝐬𝐞𝐬: Curio.Bio closes $380M Pro Rata Series A Fund 💰 + 3 more stories 𝐈𝐧𝐯𝐞𝐬𝐭𝐦𝐞𝐧𝐭𝐬: GenScript ProBio debuts new plasmid and viral vector manufacturing site 🏭 𝐌𝐞𝐫𝐠𝐞𝐫𝐬 & 𝐀𝐜𝐪𝐮𝐢𝐬𝐢𝐭𝐢𝐨𝐧𝐬: SK Bioscience buys controlling stake in IDK Biologika for $244M 💼 + 2 more stories 𝐏𝐚𝐫𝐭𝐧𝐞𝐫𝐬𝐡𝐢𝐩𝐬: Slope and big pharma form Biospecimen Management Consortium 🤝 𝐏𝐨𝐥𝐢𝐭𝐢𝐜𝐬 & 𝐏𝐨𝐥𝐢𝐜𝐲: Medicare patients to pay less on 64 drugs 💵 + 1 more story 𝐏𝐮𝐛𝐥𝐢𝐜 𝐇𝐞𝐚𝐥𝐭𝐡: CDC beefs up RSV vaccine recommendation for older adults 💉 All this and more in today's TLDR Biotech newsletter - link to the latest issue: https://lnkd.in/gUdj7wwb Or subscribe to get it straight to your inbox: https://lnkd.in/gecXctqM #tldrbiotech #biotechnews #pharmanews